Eli Lilly is set to post earnings Thursday morning, with the stock seen potentially sinking to its lowest level in months ...

Eli Lilly alleged that Empower lured customers away from their brand-name GLP-1 products and toward the pharmacy's ...

But direct-to-patient drug sales can help with make more affordable, argue HealthDyne’s David Skomo and Sarah Thomas ...

Purdue University receives $20 million to establish the Purdue Institute for Healthcare Systems Innovation, aiming to improve ...

Leqembi, which was approved in 2023 to treat the mind-robbing disease, generated $168 million in sales, up 74 percent from ...

The YMCA of Greater Houston hosted its annual Dancing with Silver Stars event Wednesday at the Bayou City Event Center. In ...

The president of the Back Bay real estate investment trust BXP said “there’s no question” that demand for life sciences lab ...

The Canadian government authorized a generic version of Ozempic developed by Dr. Reddy's Laboratories, making it the first G7 ...

Eli Lilly and Co. is taking another step to bolster its genetic medicine portfolio, this time through a $2.25 billion deal ...

Through two pioneering studies, Amgen and AstraZeneca will share study data with FDA scientists as it’s accrued. Elsewhere, ...

As of April 23, 2026, a majority of analysts covering the stock have a Buy rating on it; that is, 77% of all covering ...

Global equities declined during Q1 2026, pulling back from all-time highs as markets responded to a combination of ...